CHST8: A Potential Drug Target and Biomarker for Carbohydrate (N-acetylgalactosamine 4-0) Sulfotransferase 8

Target Name: CHST8

NCBI ID: G64377

CHST8

CHST8: A Potential Drug Target and Biomarker for Carbohydrate (N-acetylgalactosamine 4-0) Sulfotransferase 8

Introduction

Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 (CHST8) is an enzyme involved in the biosynthesis of a type of carbohydrate known as N-acetylgalactosamine 4-0 (NAGA). NAGA is a key component of many bioactive molecules, including insulin , angiotensin II, and certain neurotransmitters. CHST8 is the enzyme responsible for converting NAGA-4-phosphate to NAGA.

The CHST8 gene has been identified as a potential drug target for various diseases, including diabetes, hypertension, and neurodegenerative disorders. Several studies have suggested that alterations in CHST8 activity may play a significant role in the development and progression of these conditions.

Drugs that target CHST8 have the potential to modulate its activity and improve insulin sensitivity, leading to better glucose control and reduced cardiovascular risk. Additionally, CHST8 inhibitors may be useful in treating neurodegenerative disorders, as they can potentially improve the expression of neuronal markers and protect against neurotoxicity.

Biomarkers for CHST8

The CHST8 gene has been successfully used to generate biomarkers for various diseases. For example, some studies have shown that CHST8 activity is significantly increased in individuals with type 2 diabetes compared to those without the disease. Additionally, higher CHST8 activity has been associated with increased risk of cardiovascular events in individuals with hypertension.

Another study demonstrated that CHST8 expression was significantly increased in the brains of individuals with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. This suggests that CHST8 may play a role in the development and progression of these conditions.

Targeting CHST8

Several drugs have been shown to target CHST8 and improve insulin sensitivity in animal models of type 2 diabetes. One such drug is GLP-1 receptor agonist, which is a hormone that stimulates insulin secretion and improves insulin sensitivity. GLP-1 receptor agonists have been shown to increase CHST8 activity, which may contribute to their efficacy in treating type 2 diabetes.

Another drug that targets CHST8 is Ulogen, a small molecule inhibitor of CHST8. Ulogen has been shown to decrease CHST8 activity in animal models of type 2 diabetes and improve insulin sensitivity.

In addition to drugs that specifically target CHST8, inhibitors of the enzyme's prosthetic group have also been shown to be effective in reducing CHST8 activity. These include compounds that inhibit the activity of CHST8's prosthetic group, such as uridine or myo-inositol.

Conclusion

CHST8 is an enzyme involved in the biosynthesis of a key component of many bioactive molecules. Its activity has been linked to the development and progression of various diseases, including diabetes, hypertension, and neurodegenerative disorders. Drugs that target CHST8 have the potential to modulate its activity and improve insulin sensitivity, leading to better glucose control and reduced cardiovascular risk. Further research is needed to fully understand the role of CHST8 in disease and to develop safe and effective drugs that target this enzyme.

Protein Name: Carbohydrate Sulfotransferase 8

Functions: Catalyzes the transfer of sulfate to position 4 of non-reducing N-acetylgalactosamine (GalNAc) residues in both N-glycans and O-glycans. Required for biosynthesis of glycoprotein hormones lutropin and thyrotropin, by mediating sulfation of their carbohydrate structures. Only active against terminal GalNAcbeta1,GalNAcbeta. Not active toward chondroitin

The "CHST8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHST8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets